Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 DDI Study of Danicopan and Rosuvastatin
NCT05708573Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoints: Maximum observed plasma drug concentration of rosuvastatin, Area under the concentration-time curve from time zero to the time of the last observed/measured nonzero concentration of rosuvastatin and 4 more. Started Feb 2023; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05708573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05708573.